Pfizer Inc said on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.
A person walks past a Pfizer logo amid the coronavirus disease pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegrisaid on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.
The drugmaker paused distribution of the drug in June, and has already recalled a number of lots of the medicine so far. Pfizer asked wholesalers and distributors on Thursday to stop the use and distribution of the tablets immediately.taking Chantix, but advised them to consult with their health care provider to check the availability of alternative treatments.
Chantix was approved by the FDA in May 2006 as a prescription medication to help adults aged 18 and over quit smoking and is typically used for 12 to 24 weeks.Sign up for our newsletter Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
New Pfizer data makes case for booster shots 6 months after primary dosesBREAKING: Pfizer demonstrates what it sees as proof that third shot will be both safe and necessary for most Americans to take, arguing that immunity wanes over time—regardless of any new variant of concern—according to new data released by the FDA.
Lire la suite »
New Pfizer data makes case for booster shots 6 months after primary dosesThe Food and Drug Administration on Wednesday released new data from Pfizer's submitted application to approve booster doses of its Covid-19 vaccine. In it, Pfizer demonstrates what it sees as proof that third shot will be both safe and necessary for most Americans to take, arguing that immunity wanes over time -- regardless of any new variant of concern. It comes two days ahead of a critical juncture in the COVID-19 vaccine booster approval process: Friday, the Food and Drug Administration's independent advisory committee (VRBPAC) is set to convene to review and discuss the latest data on potential booster doses of the Pfizer vaccine.
Lire la suite »
Pfizer says data suggests vaccine boosters needed for waning vaccine efficacyPfizer told the FDA Wednesday that data from its clinical trials suggests a third shot of its coronavirus vaccine may be necessary six months after the second dose because of waning efficacy.Why it matters: The FDA's advisory committee on Friday is expected to review Pfizer's clinical trials and other supporting and conflicting data on coronavirus booster shots and make recommendations on whether more Americans 16 years and older should receive an extra dose.Stay on top of the latest market tren
Lire la suite »
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Lire la suite »
Pfizer Vaccine Still Effective, FDA Says Days Before Review Of Booster ProposalThe Biden administration has planned to launch a booster shot campaign for the general public as early as next week.
Lire la suite »